Skip to main content
. 2017 Dec 22;11(3):261–266. doi: 10.1111/cts.12532

Figure 5.

Figure 5

Kaplan–Meier curves showing overall survival (OS) in patients with relapsed or refractory multiple myeloma receiving elotuzumab plus lenalidomide and dexamethasone (“Elotuzumab”) or lenalidomide and dexamethasone (“Control”). Figure from Dimopoulos, M.A. et al. Br. J. Haematol. 178, 896–905 (2017). Reprinted with permission from John Wiley & Sons ©2017.